Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis-Reference-Cited by-同舟云学术

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Published:2006 Issue:1 Volume:45 Page:118-127
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Nakamura Minoru,Kondo Hisayoshi,Mori Tsuyoshi,Komori Atsumasa,Matsuyama Mutsumi,Ito Masahiro,Takii Yasushi,Koyabu Makiko,Yokoyama Terufumi,Migita Kiyoshi,Daikoku Manabu,Abiru Seigo,Yatsuhashi Hiroshi,Takezaki Eiichi,Masaki Naohiko,Sugi Kazuhiro,Honda Koichi,Adachi Hiroshi,Nishi Hidehiro,Watanabe Yukio,Nakamura Yoko,Shimada Masaaki,Komatsu Tatsuji,Saito Akira,Saoshiro Takeo,Harada Hideharu,Sodeyama Takeshi,Hayashi Shigeki,Masumoto Akihide,Sando Takehiro,Yamamoto Tetsuo,Sakai Hironori,Kobayashi Masakazu,Muro Toyokichi,Koga Michiaki,Shums Zakera,Norman Gary L.,Ishibashi Hiromi

Publisher

Wiley

Subject

Hepatology

Reference46 articles.

1. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years

2. Antimitochondrial Antibodies in Primary Biliary Cirrhosis

3. Nuclear Envelope Protein Autoantibodies in Primary Biliary Cirrhosis

4. Antinuclear Antibodies in Primary Biliary Cirrhosis

Cited by 316 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reflecting on a decade of the international consensus on ANA patterns (ICAP): Accomplishments and challenges from the perspective of the 7th ICAP workshop;Autoimmunity Reviews;2024-09

2. Long-term outcomes in patients with primary biliary cholangitis complicated with CREST syndrome;Scientific Reports;2024-06-19

3. Autoantibodes to GP210 are a metric for UDCA responses in primary biliary cholangitis;Journal of Translational Autoimmunity;2024-06

4. Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid;European Journal of Internal Medicine;2024-06

5. Linee guida SIPMeL per la determinazione degli autoanticorpi nella diagnosi delle malattie autoimmuni del fegato;La Rivista Italiana della Medicina di Laboratorio;2024-04